Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.1/19063 |
Resumo: | Fingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study was to evaluate whether fingolimod treatment modifies PPAR and CD36 gene expression as part of its action mechanisms. Serum lipoprotein profiles and PPAR and CD36 gene expression levels in peripheral leukocytes were analysed in 17 female MS patients before and at 6 and 12 months after fingolimod treatment initiation. Clinical data during the follow-up period of treatment were obtained. We found that fingolimod treatment increased HDL-Cholesterol and Apolipoprotein E levels and leukocyte PPAR gamma and CD36 gene expression. No correlations were found between lipid levels and variations in PPAR gamma and CD36 gene expression. PPAR gamma and CD36 variations were significantly correlated during therapy and in patients free of relapse and stable disease. Our results suggest that PPAR gamma and CD36-mediated processes may contribute to the mechanisms of action of fingolimod in MS. Further studies are required to explore the relation of the PPAR gamma/CD36 pathway to the clinical efficacy of the drug and its involvement in the pathogenesis of the disease. |
id |
RCAP_031bc429aba5662f1f23bb405d7ccc9b |
---|---|
oai_identifier_str |
oai:sapientia.ualg.pt:10400.1/19063 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosisFingolimodPeroxisome proliferator-activated receptors (PPAR)Cluster of differentiation 36 (CD36)LipoproteinsMultiple sclerosisFingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study was to evaluate whether fingolimod treatment modifies PPAR and CD36 gene expression as part of its action mechanisms. Serum lipoprotein profiles and PPAR and CD36 gene expression levels in peripheral leukocytes were analysed in 17 female MS patients before and at 6 and 12 months after fingolimod treatment initiation. Clinical data during the follow-up period of treatment were obtained. We found that fingolimod treatment increased HDL-Cholesterol and Apolipoprotein E levels and leukocyte PPAR gamma and CD36 gene expression. No correlations were found between lipid levels and variations in PPAR gamma and CD36 gene expression. PPAR gamma and CD36 variations were significantly correlated during therapy and in patients free of relapse and stable disease. Our results suggest that PPAR gamma and CD36-mediated processes may contribute to the mechanisms of action of fingolimod in MS. Further studies are required to explore the relation of the PPAR gamma/CD36 pathway to the clinical efficacy of the drug and its involvement in the pathogenesis of the disease.Frontiers MediaSapientiaFerret-Sena, VéroniqueCapela, CarlosMacedo, AnaSalgado, António VascoDerudas, BrunoStaels, BartSena, Armando2023-02-13T10:15:57Z2022-122022-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/19063eng1662-509910.3389/fnmol.2022.1077381info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:31:28Zoai:sapientia.ualg.pt:10400.1/19063Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:08:44.569285Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis |
title |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis |
spellingShingle |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis Ferret-Sena, Véronique Fingolimod Peroxisome proliferator-activated receptors (PPAR) Cluster of differentiation 36 (CD36) Lipoproteins Multiple sclerosis |
title_short |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis |
title_full |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis |
title_fullStr |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis |
title_full_unstemmed |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis |
title_sort |
Fingolimod treatment modulates PPARγ and CD36 gene expression in women with multiple sclerosis |
author |
Ferret-Sena, Véronique |
author_facet |
Ferret-Sena, Véronique Capela, Carlos Macedo, Ana Salgado, António Vasco Derudas, Bruno Staels, Bart Sena, Armando |
author_role |
author |
author2 |
Capela, Carlos Macedo, Ana Salgado, António Vasco Derudas, Bruno Staels, Bart Sena, Armando |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Sapientia |
dc.contributor.author.fl_str_mv |
Ferret-Sena, Véronique Capela, Carlos Macedo, Ana Salgado, António Vasco Derudas, Bruno Staels, Bart Sena, Armando |
dc.subject.por.fl_str_mv |
Fingolimod Peroxisome proliferator-activated receptors (PPAR) Cluster of differentiation 36 (CD36) Lipoproteins Multiple sclerosis |
topic |
Fingolimod Peroxisome proliferator-activated receptors (PPAR) Cluster of differentiation 36 (CD36) Lipoproteins Multiple sclerosis |
description |
Fingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study was to evaluate whether fingolimod treatment modifies PPAR and CD36 gene expression as part of its action mechanisms. Serum lipoprotein profiles and PPAR and CD36 gene expression levels in peripheral leukocytes were analysed in 17 female MS patients before and at 6 and 12 months after fingolimod treatment initiation. Clinical data during the follow-up period of treatment were obtained. We found that fingolimod treatment increased HDL-Cholesterol and Apolipoprotein E levels and leukocyte PPAR gamma and CD36 gene expression. No correlations were found between lipid levels and variations in PPAR gamma and CD36 gene expression. PPAR gamma and CD36 variations were significantly correlated during therapy and in patients free of relapse and stable disease. Our results suggest that PPAR gamma and CD36-mediated processes may contribute to the mechanisms of action of fingolimod in MS. Further studies are required to explore the relation of the PPAR gamma/CD36 pathway to the clinical efficacy of the drug and its involvement in the pathogenesis of the disease. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-12 2022-12-01T00:00:00Z 2023-02-13T10:15:57Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.1/19063 |
url |
http://hdl.handle.net/10400.1/19063 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1662-5099 10.3389/fnmol.2022.1077381 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133334277718016 |